Issue Date: October 22, 2007
Optimism Prevails For Fine Chemicals
BETWEEN 2000 AND 2005, pharmaceutical outsourcing was going nowhere, and the fine chemicals business nearly came to a standstill. Developers withdrew many late-stage and marketed products, leaving only a trickle of new projects coming out of the drug development pipeline. To cut costs, some drug firms moved production inside, using their own plants to make a diminishing number of drug candidates. Custom chemical manufacturers were left with limited business, excess capacity, and low-cost competition emerging . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society